ProKidney reached a significant clinical milestone in the second quarter of 2026 by completing enrollment for its Phase 3 PROACT 1 accelerated approval efficacy analysis. The company reported a net loss of $46.4 million as it scaled research activities for its lead candidate, rilparencel, while maintaining a liquidity position sufficient to fund operations into mid-2027.
Key Highlights
- Completed enrollment for the PROACT 1 accelerated approval analysis, with pivotal topline eGFR slope results now anticipated in the second quarter of 2027.
- Ended the quarter with $181.6 million in cash and marketable securities, down from $224.9 million in the previous quarter.
- Research and development expenses increased to $36.1 million compared to $25.9 million in the prior year, driven by an $8.7 million rise in clinical study and manufacturing costs.
- Management remains on track to complete full enrollment of approximately 470 patients for the PROACT 1 confirmatory analysis in the second half of 2026.